📣 VC round data is live. Check it out!
- Public Comps
- Fulcrum Therapeutics
Fulcrum Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Fulcrum Therapeutics and similar public comparables like Karyopharm Therapeutics, Atrium Therapeutics, Saniona, BioInvent International and more.
Fulcrum Therapeutics Overview
About Fulcrum Therapeutics
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Founded
2015
HQ

Employees
55
Website
Financials (LTM)
Market Cap
$209M
Valuation Multiples
Start free trialFulcrum Therapeutics Financials
Fulcrum Therapeutics reported last 12-month revenue of - and negative EBITDA of ($72M).
In the same LTM period, Fulcrum Therapeutics generated - in gross profit, ($72M) in EBITDA losses, and had net loss of ($70M).
Revenue (LTM)
Fulcrum Therapeutics P&L
In the most recent fiscal year, Fulcrum Therapeutics reported revenue of - and EBITDA of ($83M).
Fulcrum Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
Fulcrum Therapeutics Stock Performance
Fulcrum Therapeutics has current market cap of $209M.
Market Cap Evolution
Fulcrum Therapeutics' stock price is $3.14.
Fulcrum Therapeutics share price decreased by 54.6% in the last 30 days, and by 54.3% in the last year.
Fulcrum Therapeutics has an EPS (earnings per share) of $-1.12.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $209M | -51.0% | -54.6% | -59.1% | -54.3% | $-1.12 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialFulcrum Therapeutics Valuation Multiples
Fulcrum Therapeutics trades at 1.6x EV/EBITDA.
EV / Revenue (LTM)
Fulcrum Therapeutics Financial Valuation Multiples
As of June 4, 2026, Fulcrum Therapeutics has market cap of $209M.
Fulcrum Therapeutics has a P/E ratio of (3.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Fulcrum Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Fulcrum Therapeutics Margins & Growth Rates
Fulcrum Therapeutics decreased EBITDA by 31% in the last fiscal year.
Fulcrum Therapeutics Margins
Fulcrum Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Fulcrum Therapeutics Operational KPIs
Fulcrum Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.5M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Fulcrum Therapeutics Competitors
Fulcrum Therapeutics competitors include Karyopharm Therapeutics, Atrium Therapeutics, Saniona, BioInvent International, Keros Therapeutics, Nkarta, Whitehawk Therapeutics, Camp4 Therapeutics, NervGen Pharma and Foghorn Therapeutics.
Most Fulcrum Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.4x | 2.5x | (2.3x) | - | |||
| (3.0x) | (3.0x) | 0.7x | - | |||
| 3.2x | - | 4.5x | 7.5x | |||
| 6.4x | 7.6x | (4.8x) | (3.6x) | |||
| (0.2x) | (0.4x) | (0.8x) | - | |||
| - | - | (0.5x) | - | |||
| 8.5x | 14.8x | (3.0x) | - | |||
| 31.3x | 24.2x | (2.2x) | (1.5x) | |||
This data is available for Pro users. Sign up to see all Fulcrum Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Fulcrum Therapeutics VC Funding History
Before going public, Fulcrum Therapeutics raised $140M in total equity funding, across 3 rounds.
Last private valuation of Fulcrum Therapeutics was $534M, after raising $80M in September 2018 from 6 Dimensions Capital, Casdin Capital, Fidelity, and 5 other investors.
Fulcrum Therapeutics Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Fulcrum Therapeutics
| When was Fulcrum Therapeutics founded? | Fulcrum Therapeutics was founded in 2015. |
| Where is Fulcrum Therapeutics headquartered? | Fulcrum Therapeutics is headquartered in United States. |
| How many employees does Fulcrum Therapeutics have? | As of today, Fulcrum Therapeutics has over 55 employees. |
| Who is the CEO of Fulcrum Therapeutics? | Fulcrum Therapeutics' CEO is Alex C. Sapir. |
| Is Fulcrum Therapeutics publicly listed? | Yes, Fulcrum Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Fulcrum Therapeutics? | Fulcrum Therapeutics trades under FULC ticker. |
| When did Fulcrum Therapeutics go public? | Fulcrum Therapeutics went public in 2019. |
| Who are competitors of Fulcrum Therapeutics? | Fulcrum Therapeutics main competitors include Karyopharm Therapeutics, Atrium Therapeutics, Saniona, BioInvent International, Keros Therapeutics, Nkarta, Whitehawk Therapeutics, Camp4 Therapeutics, NervGen Pharma, Foghorn Therapeutics. |
| What is the current market cap of Fulcrum Therapeutics? | Fulcrum Therapeutics' current market cap is $209M. |
| Is Fulcrum Therapeutics profitable? | No, Fulcrum Therapeutics is not profitable. |
| What is the current EBITDA of Fulcrum Therapeutics? | Fulcrum Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Fulcrum Therapeutics? | Current EBITDA multiple of Fulcrum Therapeutics is 1.6x. |
| What is the current FCF of Fulcrum Therapeutics? | Fulcrum Therapeutics' last 12 months FCF is ($60M). |
| What is the current EV/FCF multiple of Fulcrum Therapeutics? | Current FCF multiple of Fulcrum Therapeutics is 2.0x. |
| How many companies Fulcrum Therapeutics has acquired to date? | Fulcrum Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Fulcrum Therapeutics has invested to date? | Fulcrum Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Fulcrum Therapeutics
Lists including Fulcrum Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.